anti obesity medication
PreclinicalSmall molecule
anti obesity medication is one of 33 small molecule programs targeting Obesity. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Actemra
RochePreclinical
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Adenocard
AstellasPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Prometrium
FerringPreclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti obesity medication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Pisa